Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) Shares Outstanding (Weighted Average) (2016 - 2026)

Ekso Bionics Holdings has reported Shares Outstanding (Weighted Average) over the past 14 years, most recently at $2.4 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 80.51% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 million, a 80.51% increase, with the full-year FY2025 number at $2.4 million, up 80.51% from a year prior.
  • Shares Outstanding (Weighted Average) reached $2.4 million in Q4 2025 per EKSO's latest filing, up from $2.2 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $25.4 million in Q1 2025, with the low at $1240.0 in Q2 2023.
  • The 5-year median for Shares Outstanding (Weighted Average) is $12.1 million (2021), against an average of $9.0 million.
  • Peak YoY movement for Shares Outstanding (Weighted Average): crashed 99.99% in 2023, then soared 97883.87% in 2024.
  • Tracing EKSO's Shares Outstanding (Weighted Average) over 5 years: stood at $12.2 million in 2021, then grew by 6.31% to $13.0 million in 2022, then increased by 6.98% to $13.9 million in 2023, then tumbled by 90.31% to $1.3 million in 2024, then skyrocketed by 80.51% to $2.4 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $2.4 million, $2.2 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.